

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4969574

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MD ANDERSON CANCER CENTER	05/18/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
<b>Street Address:</b>	NIH, 6705 ROCKLEDGE DRIVE
<b>Internal Address:</b>	SUITE 310
<b>City:</b>	BETHESDA
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20892
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	10489071
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	7137459639
<b>Email:</b>	KNapolitano@mdanderson.org
<b>Correspondent Name:</b>	ANDREW P. DENNIS
<b>Address Line 1:</b>	7007 BERTNER AVE
<b>Address Line 2:</b>	1MC9.2128
<b>Address Line 4:</b>	HOUSTON, TEXAS 77030
<b>NAME OF SUBMITTER:</b>	ANDREW P. DENNIS
<b>SIGNATURE:</b>	/Andrew P. Dennis/
<b>DATE SIGNED:</b>	05/21/2018
This document serves as an Oath/Declaration (37 CFR 1.63).	
<b>Total Attachments: 1</b>	
source=00-025CIP1#page1.tif	

# License to the United States Government

(Sign and submit this executed document to the United States Patent and Trademark Office – Electronic Patent Assignment System (EPAS) <http://epas.uspto.gov>)

Executive Order 9424: Government Support License (Government Support Clause)

Invention title: Compositions and Methods of Use of Targeting Peptides Against Placenta and Adipose Tissues

Inventor(s): Wadih Arap, Renata Pasqualini, Mikhail G. Kolonin

U.S. Filing/Issue Date: 10/13/2004

Patent or Application Serial No: 10/489,071

Grant/Contract Number(s): CA078512, CA082713, CA082976, CA080910, CA090270, DAMD17-98-1-8581, DAMD17-98-1-8041

Foreign Applications filed/intended in (countries): \_\_\_\_\_

The invention identified above is a subject invention under 35 U.S.C. 200, et seq., and the Standard Patent Rights Clause at 37 CFR 401.14, FAR 52.227-11 or FAR 52.227-12 (if applicable) which are included among the terms of the above identified grant or contract award from the United States Government. This document is confirmatory of:

1. As required by 37 CFR 401.14 (f) (2) and Executive Order 9424:

This invention was made with government support under Grant/Contract Number(s) CA078512, CA082713, CA082976, CA080910, CA090270 awarded by the National Institutes of Health. The government has certain rights in the invention. and DAMD17-98-1-8581, DAMD17-98-1-8041 awarded by the U.S Department of the Army

2. All other rights acquired by the Government by reason of the above identified grant/contract award and the laws and regulations that are applicable to the award.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this 18<sup>th</sup> day of May 2018.

By: Andrew P. Dennis, PhD  
Institutional Business Official Printed Name and Title

Andrew P. Dennis  
Signature

Title Managing Director, Office of Technology Commercialization

For MD Anderson Cancer Center  
Grantee/Contractor Organization

At OFFICE OF TECHNOLOGY COMMERCIALIZATION 7007 Bertner Ave., 1MC9.2126, Houston, Texas 77030-3907  
Business Address